After investing over a decade of time, effort and money into the Critical Care Reviews website, I've decided it's time to refocus back to our main area - critical care trials. Over this period the website has expanded to almost 9000 webpage, consuming vast amounts of time to maintain.
It will take a few months to import the main sections of the old site, so please bear with me as this happens. The new site will be slicker and more streamlined, as well as more visually atractive. All the usual popular features will be maintained, such as journal watch, newsletters, podcasts, books and meeting materials.
The website is far from ideal for going live, but the eCCR21 section is complete, forcing an early move. Critical Care Reviews will continue to be the website to use to stay up-to-date with the latest literature. I hope you enjoy the new look and refocus. I'll have the site repopulated as quick as I can
It's less than a week to eCCR21, featuring 5 major trial results, 14 of the most important critical care trials reported in 2020 and 4 additional talks. The entire meeting is being live streamed for free across vimeo, twitter, LinkedIn and, of course, the Critical Care Reviews website.
Registration is open and required for claiming CPD / CME points. The meeting has been approved for 18 points by the Royal College of Anaesthetists. For those not wihing to claim CPD / CME, just watch the live stream on one of the many platforms on which it is available. If you are not free to watch it live, everything will be available afterwards for later viewing. Our talks are released in both video and audio formats.
Please feel free to tell your friends and colleagues.
In 1824 infants born prematurely between 22 and 26 weeks and weighing less than 1000 g, a higher hemoglobin threshold for red-cell transfusion did not improve survival without neurodevelopmental impairment at 22 to 26 months of age, corrected for prematurity
Kirpalani et al. N Engl J Med 2020; 383:2639-2651
M.Moira | Shutterstock
In a pre-print paper, the REMAP-CAP trial investigators have reported efficacy with interleukin 6 receptor anatgonists in critically ill patients with COVID-19. Hospital mortality was 28.0% (98/350) for tocilizumab, 22.2% (10/45) for sarilumab and 35.8% (142/397) for control.
In 10,406 randomised patients, with 1873 reported deaths, there was no significant difference in the primary endpoint of 28-day mortality -18% convalescent plasma vs. 18% usual care alone; risk ratio 1.04 [95% confidence interval 0.95-1.14]; p=0.34.
Prof Peter Horby, Tweet, Jan 15th
Three large randomised controlled trials, ATTACC, @ACTIV4a, and REMAP-CAP, have, for futility, halted recruitment to their therapeutic anticoagulation arms in critically ill patients with COVID-19.
In this trial PCT-guided antimicrobial treatment in sepsis was effective in reducing infection-associated adverse events like infections by multidrug-resistant organisms and Clostridioides difficile, as well as in-hospital and 28-day mortality.
Am J Respir Crit Care Med 2021;202(3):202–210
January 17th 2021
Lancet 2020;epublished December 21st
JAMA Intern Med 2020;epublished October 26th